Bavarian Nordic If there is one thing that successful Danish companies have in common with one another, it is the clear recognition of abundant opportunities outside the motherland. “Danish companies’ strengths lie in their ability to build on what they have inherited from Denmark but to also look outward and be…
Biotechnology The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic shift towards becoming a semi-virtual model company. He also considers the importance of creating global links to capital as a…
Basic Research A leading figure in the Taiwanese pharmaceutical sector, Lee divulges the practicalities behind ECFA, the free trade agreement that was signed between China and Taiwan in 2010 but has not yet come into full force; questions whether a lack of multinational investment has been a major disadvantage for Taiwan; explains…
drug development BIOTECanada is the national trade association for Canada’s biotech industry. Andrew Casey, the group’s CEO, discusses the impact of IP regulation on emerging biotech companies, incentives for developing the sector on a national level, and offers perspectives on tax policy and its impact on drug development. How does BIOTECanada actively…
JHL Biotech Dr. Karen Wen of Mycenax likened her company to a “kitchen.” Would you say the same of JHL? Racho Jordanov (RJ): We might indeed liken ourselves to a kitchen. But I would add this: there are a lot of cookbooks out there, but…
Biogen Idec Having experienced many years at big pharmaceutical companies, you moved into the biotech sector by joining Biogen Idec late 2010. What made you decide to switch? To me, it was an easy decision. It was an appealing challenge to join a company that was in growth mode but where many…
Biotech As in many emerging countries, it is taking a while for Mexican legislation to catch up with the latest technologies. Alejandra Mendoza, general manager of Genzyme Mexico, says that regulation has been the main challenge her firm has had to face. “We were pioneers in biotech in Mexico, so we…
Eucodis Bioscience Previously you worked for a pharmaceutical company, before moving to head up Eucodis Bioscience. What was your main motivation for switching from the pharmaceutical to the industrial biotech industry? The main motivation was the portfolio of the company and that it is in biotech. Austria is not a big country…
BioSingapore In addition to being the director of strategic planning at Quintiles you are also the Chairman of BioSingapore. In this context, can you please introduce BioSingapore and describe its main objectives? BioSingapore was created in 2004 by the Singapore Economic Development Board (EDB) to create an interactive platform for the…
Nobel Biocare Mexico Nobel Biocare is a world leader in innovative restorative and esthetic dental solutions. How is the Mexican audience responding to your products? There is a wide segment of the Mexican market that matches our global value proposition. Even if Mexico had a different income structure, there is a broad part…
Biotest Austria What initially attracted you to Biotest back in 2001 and what do you think attracts industry professionals to Biotest today? I started my pharmaceutical career at Behring in Austria, doing basic jobs such as visiting doctors as a representative, and I also worked as a product manager. During this time…
Ausbiotech What have been the focus areas for the association in improving the wellbeing of the life science biotech industry and what have been the key milestones/achievements since 2008 in providing representation and services to promote the global growth of Australian biotechnology? In addition to the financial crisis the government decided…
See our Cookie Privacy Policy Here
